Reviewed August 2026 by the Corydalis Labs Technical Team. How we research and review.
The basics
13-OH is shorthand for 13-OH Corydalis Yanhusuo, a hydroxylated alkaloid derived from Corydalis yanhusuo rhizome and related to that plant’s principal alkaloid tetrahydropalmatine (THP). It is used in botanical formulations as a synergist at 25–40 mg per serving. Full technical reference.
The "13-OH" part records where a hydroxyl group sits on the molecule — at the 13 position. "Corydalis Yanhusuo" names the plant it comes from. Together: 13-OH Corydalis Yanhusuo.
No. Different plant, different parent compound, different alkaloid family, different regulatory position. The names share a convention, nothing more. Full comparison.
No. Kratom is Mitragyna speciosa. 13-OH comes from Corydalis yanhusuo, an unrelated plant in the poppy family, and contains no kratom-derived material.
It is derived from plant material — Corydalis yanhusuo rhizome. It is a derivative of a naturally occurring alkaloid rather than a compound designed from scratch to imitate something else.
Tetrahydropalmatine, the principal alkaloid of Corydalis yanhusuo and the parent of 13-OH. An isoquinoline alkaloid, characterised in the literature for decades. Full page.
A mitragynine product with 13-OH blended in, usually at 25–40 mg per serving. The most common application. Full explanation.
Formulation
25–40 mg in a blend, most commonly 30 mg. Standalone use needs above 100 mg and should be paired with a stimulant. Dosing detail.
At 30 mg inclusion, about 33,333 servings — roughly 16,600 two-count blisters. At 25 mg, 40,000 servings; at 40 mg, 25,000. Run your own numbers.
Not well, at commercial inclusion rates. It is a synergist — subtle alone, substantial in a blend. We say this plainly because your own evaluation would tell you within an afternoon. Why.
Mitragynine most commonly; kava and kanna for kratom-free builds; caffeine and other stimulants for standalone products. Functional additions we work with routinely include L-theanine, GABA, 5-HTP, agmatine, willow bark, valerian root, and piperine. Detail.
That is the most commonly reported benefit. How much depends on your starting formula, which is why a three-sample bench trial is worth running properly. How to run one.
Yes. Most brands start from one of three proven builds and adjust with our formulation team. You do not need a finished formula to start a conversation.
Cross-scored tablets in counts from 1 to 50, and liquid shots at 15, 30, and 60 ml. Minimums are 25,000 tablets or 15,000 shots. Co-packing detail.
Legal and regulatory
As of August 2026, neither 13-OH, tetrahydropalmatine, nor Corydalis extract appears on the federal controlled substance schedules or the DEA List I/II chemical lists. That is a statement about controlled-substance status; other rules govern how a finished product may be formulated and marketed. Review both with your own counsel. Full summary.
We are not aware of state controlled-substance scheduling of corydalis alkaloids as of August 2026. State kratom acts, which regulate Mitragyna speciosa, do not reach corydalis-only products by their terms. Verify current law in your markets before selling. State detail.
Not on its own — those statutes define their scope around Mitragyna speciosa and its alkaloids. A product containing both mitragynine and 13-OH remains within their scope because of the mitragynine. The kratom-free path.
Any substance can become subject to regulatory action, and nobody can promise otherwise. What differs here is the starting position: the compounds recently scheduled in this category were all derivatives of chemistry regulators were already examining. Corydalis alkaloids are not. The reasoning, with sources.
FDA issued warning letters to firms marketing 7-OH products and DEA filed notices of intent to temporarily schedule it in July 2026; several states acted earlier. Current status.
Both were named in the same July 2026 DEA notices. Articles recommending them as 7-OH replacements predate that action. What happened.
State kratom act age requirements are triggered by kratom content, so a corydalis-only product does not trigger them by their terms. We nonetheless recommend positioning any product in this category as 21+ — it is the responsible default and it protects the category. Marketing guidance.
Buying and manufacturing
One kilogram for bulk material. For co-packing, 25,000 tablets or 15,000 shots. Bulk detail.
Yes, and we keep them in stock. A 10 gram sample kit is $400 and includes finished tablet and shot samples so you can evaluate the material and the format together.
93–98% active, reported lot by lot on the certificate of analysis. Our testing programme.
Yes — email sales@corydalislabs.com and we will send a representative certificate for current material, plus our method parameters if your lab wants them.
Chromatography. The two separate cleanly — THP at 15.0 minutes, 13-OH at 18.8. Send material to any competent analytical lab and check. The method.
Co-packing runs fifteen days from the point your packaging arrives with us. Demand is rising and the queue fills, so lead times extend as it does — a spec locked earlier holds an earlier slot.
Bulk material is paid in full before shipping. Co-packing runs are 70% deposit with the balance due before shipping.
No. We supply businesses only — brands, manufacturers, and distributors — and we do not sell finished product under our own label, so we are never competing with our customers.
We are a United States manufacturer and produce in our own facility. We do not publish the facility address.
Within one business day, every time. Request a quote.
Question not covered? Email sales@corydalislabs.com. We answer, and if it is a question other people are likely to have, it ends up on this page.